Cervical Cancer Deaths Down Following HPV Vaccine Introduction
Reductions in cervical cancer incidence, mortality in the U.S. greater for those aged 15 to 24 years than those aged 25 to 29, 30 to 39 years.
Reductions in cervical cancer incidence, mortality in the U.S. greater for those aged 15 to 24 years than those aged 25 to 29, 30 to 39 years.
Fewer than expected cervical cancers, CIN3 cases seen among vaccinated cohorts after introduction of HPV immunization program in England.
Cutaneous beta-human papillomavirus (HPV) may predict development of cutaneous squamous cell carcinoma (cuSCC).
Rates low for 18- to 21-year-olds reporting vaccination at any age or initiating in young adulthood
For most of the study period, higher rates of HPV vaccination initiation and up-to-date rates were seen for non hispanic blacks.
Low expression of the HPV-related marker cyclin D1 appears to be an independent prognostic marker in Barrett high-grade dysplasia and esophageal adenocarcinoma.
More than half of bimanual exams, >70 percent of Pap tests in women aged 15 to 20 years unnecessary
Studies based on searching Vaccine Adverse Event Reporting System, six Vaccine Safety Datalink sites
No significant difference found in detection of CIN2+ or treatment with intervention versus usual care
One dose compared with two or three doses in preventing cervical precancer in high-coverage settings